Jacksonville, Florida
CNS medication trials in Jacksonville, FL
30 CNS medication studies are recruiting participants at sites in Jacksonville as of November 17, 2026, according to ClinicalTrials.gov. CNS Medication Trials can help you understand your options and connect with a study team.
- No cost to ask
- Taking part is voluntary
- Studies are independently reviewed
Jacksonville at a glance
- 30 studies are recruiting at a site in Jacksonville.
- By phase: Early Phase 1 (1), Phase 1 (1), Phase 1/2 (1), Phase 2 (12), Phase 3 (12), Phase 4 (3).
- By sponsor: industry (27), university, hospital or other (3).
- By research area: Depression (13), ADHD (5), Epilepsy (4), Parkinson's Disease (3), Migraine (2), Multiple Sclerosis (2), Schizophrenia (1).
- Most recent update to one of these records: November 17, 2026.
Depression studies recruiting in Jacksonville
Basic details from each study's public record. Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.
A Study to Evaluate the Safety and Efficacy of ALKS 7290 as an Adjunctive Therapy to Antidepressants in Adult Participants With Major Depressive Disorder
- Phase 2
- Ages 18 to 65
- All sexes
- Sponsor
- Alkermes, Inc.
- Study site
- Alkermes Investigator Site
- Registry record
- NCT07901179 · updated
Double-blind, Placebo-controlled Study in Adults With Major Depressive Disorder
- Phase 2
- Ages 18 to 70
- All sexes
- Sponsor
- Supernus Pharmaceuticals, Inc.
- Study site
- CNS Healthcare - Jacksonville
- Registry record
- NCT07226661 · updated
A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder
- Phase 3
- Ages 18 to 85
- All sexes
- Sponsor
- Cybin IRL Limited
- Study site
- CNS Healthcare
- Registry record
- NCT06793397 · updated
A Study to Evaluate the Efficacy and Safety of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 Study)
- Phase 2
- Ages 18 to 65
- All sexes
- Sponsor
- Seaport Therapeutics
- Study site
- Seaport Investigator Site
- Registry record
- NCT07065240 · updated
A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend)
- Phase 3
- Ages 18 to 74
- All sexes
- Sponsor
- Definium Therapeutics US, Inc.
- Study site
- Clinical Neuroscience Solutions, LLC (Jacksonville)
- Registry record
- NCT07592689 · updated
A Study to Evaluate TNX-102 SL Monotherapy Versus Placebo in Participants With Major Depressive Disorder (MDD)
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- Tonix Pharmaceuticals, Inc.
- Registry record
- NCT07621237 · updated
ALTO-100 in Bipolar Disorder With Depression (BD-D)
- Phase 2
- Ages 18 to 70
- All sexes
- Sponsor
- Alto Neuroscience
- Registry record
- NCT06656416 · updated
Clinical Assessment of Response in the Treatment of Depression With Daytime Sleepiness Using Solriamfetol
- Phase 3
- Ages 18 to 65
- All sexes
- Sponsor
- Axsome Therapeutics, Inc.
- Registry record
- NCT07484217 · updated
Subanesthetic Ketamine Infusions for Depressive Symptoms in Intensive Care Unit Patients
- Phase 2
- Ages 18 to 99
- All sexes
- Sponsor
- Hospital Italiano de Buenos Aires
- Study site
- Mayo Clinic
- Registry record
- NCT07639359 · updated
Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder
- Phase 2
- Ages 18 to 64
- All sexes
- Sponsor
- Syndeio Biosciences, Inc
- Study site
- Clinical Neuroscience Solutions, Inc.
- Registry record
- NCT06547489 · updated
A Study to Assess Change in Disease Activity and Adverse Events of Oral Icalcaprant in Adult Participants With Major Depressive Disorder
- Phase 2
- Ages 18 to 65
- All sexes
- Sponsor
- AbbVie
- Study site
- Cns Healthcare - Jacksonville /ID# 277658
- Registry record
- NCT07276997 · updated
Study of ABX-002 for the Adjunctive Treatment of Major Depressive Disorder (AMPLIFY)
- Phase 2
- Ages 18 to 65
- All sexes
- Sponsor
- Autobahn Therapeutics, Inc.
- Study site
- Autobahn Site #101
- Registry record
- NCT06633016 · updated
A Study to Evaluate the Efficacy of AXS-05 Compared to Bupropion in Preventing the Relapse of Depressive Symptoms
- Phase 4
- Ages 18 to 65
- All sexes
- Sponsor
- Axsome Therapeutics, Inc.
- Registry record
- NCT06223880 · updated
Source: ClinicalTrials.gov. Data processed . See every depression study recruiting in Jacksonville, FL on ClinicalTrials.gov.
Schizophrenia studies recruiting in Jacksonville
Safety and Tolerability Trial of Lumateperone in Pediatric Patients With Schizophrenia, Bipolar Disorder or Autism Spectrum Disorder
- Phase 3
- Ages 5 to 17
- All sexes
- Sponsor
- Intra-Cellular Therapies, Inc.
- Study site
- Green Leaf Clinical Trials
- Registry record
- NCT06229210 · updated
Source: ClinicalTrials.gov. Data processed . See every schizophrenia study recruiting in Jacksonville, FL on ClinicalTrials.gov.
ADHD studies recruiting in Jacksonville
Forward Treatment of Attention Deficit and Hyperactivity Using Solriamfetol (FOCUS-2)
- Phase 3
- Ages 6 to 11
- All sexes
- Sponsor
- Axsome Therapeutics, Inc.
- Registry record
- NCT07717879 · updated
Forward Treatment of Attention Deficit and Hyperactivity Using Solriamfetol (FOCUS-3)
- Phase 3
- Ages 12 to 17
- All sexes
- Sponsor
- Axsome Therapeutics, Inc.
- Registry record
- NCT07717892 · updated
A Study to Test the Effects of Centanafadine in Adults With Attention-deficit/Hyperactivity Disorder and Emotional Dysregulation
- Phase 3
- Ages 18 to 65
- All sexes
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Study site
- CNS Healthcare - Jacksonville (Clinical Neuroscience Solutions - Jacksonville)
- Registry record
- NCT07759154 · updated
A Study to Evaluate Safety and Efficacy of ALKS 7290 Compared With Placebo in Adult Participants With Attention Deficit Hyperactivity Disorder (ALKS 7290-201)
- Phase 2
- Ages 18 to 65
- All sexes
- Sponsor
- Alkermes, Inc.
- Study site
- Alkermes Investigational Site
- Registry record
- NCT07755410 · updated
Evaluation of SPN-812 (Viloxazine Extended-release Capsule) in Preschool-age Children With ADHD
- Phase 4
- From 48 months, up to 69 months
- All sexes
- Sponsor
- Supernus Pharmaceuticals, Inc.
- Study site
- Clinical Neuroscience Solutions, Inc.
- Registry record
- NCT04781140 · updated
Source: ClinicalTrials.gov. Data processed . See every ADHD study recruiting in Jacksonville, FL on ClinicalTrials.gov.
Parkinson's disease studies recruiting in Jacksonville
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Study site
- Mayo Clinic Hospital ( Site 0013)
- Registry record
- NCT06966700 · updated
Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Study site
- Mayo Clinic in Florida-Mayo Clinic Comprehensive Cancer Center ( Site 0133)
- Registry record
- NCT06170788 · updated
Safety, PK and Biodistribution of 18F-OP-801 in Patients With ALS, AD, MS, PD and Healthy Volunteers
- Phase 1/2
- Ages 18 to 80
- All sexes
- Sponsor
- Ashvattha Therapeutics, Inc.
- Study site
- Mayo Clinic Jacksonville
- Registry record
- NCT05395624 · updated
Source: ClinicalTrials.gov. Data processed . See every Parkinson's disease study recruiting in Jacksonville, FL on ClinicalTrials.gov.
Multiple sclerosis (MS) studies recruiting in Jacksonville
PHENOGENE-1A (Cromolyn) Treatment in Patients With Mild to Moderate ALS
- Phase 2
- Ages 18 to 75
- All sexes
- Sponsor
- PhenoNet, Inc.
- Study site
- Mayo Clinic Jacksonville
- Registry record
- NCT07142291 · updated
AMX0114 in Adult Participants With Amyotrophic Lateral Sclerosis
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- Amylyx Pharmaceuticals Inc.
- Study site
- Mayo Clinic in Florida
- Registry record
- NCT06665165 · updated
Source: ClinicalTrials.gov. Data processed . See every multiple sclerosis study recruiting in Jacksonville, FL on ClinicalTrials.gov.
Epilepsy studies recruiting in Jacksonville
A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures
- Phase 3
- Ages 12 and older
- All sexes
- Sponsor
- Xenon Pharmaceuticals Inc.
- Study site
- Mayo Clinic Florida
- Registry record
- NCT05667142 · updated
A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures (X-TOLE3)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Xenon Pharmaceuticals Inc.
- Study site
- Mayo Clinic Florida
- Registry record
- NCT05716100 · updated
Optimizing Therapy in Epilepsy Using Seizure Forecasts Via EEG and Wearables
- Early Phase 1
- Ages 18 to 75
- All sexes
- Sponsor
- Mayo Clinic
- Study site
- Mayo Clinic
- Registry record
- NCT07012148 · updated
Safety and Tolerability Study of SPN-817 in Adult Patients With Treatment Resistant Epilepsy
- Phase 2
- Ages 18 to 70
- All sexes
- Sponsor
- Supernus Pharmaceuticals, Inc.
- Study site
- Green Leaf Clinical Trials, LLC
- Registry record
- NCT05518578 · updated
Source: ClinicalTrials.gov. Data processed . See every epilepsy study recruiting in Jacksonville, FL on ClinicalTrials.gov.
Migraine studies recruiting in Jacksonville
Comparative Effectiveness of Migraine Preventive Medications: The APT Comparison Study
- Phase 4
- Ages 18 to 70
- All sexes
- Sponsor
- Mayo Clinic
- Study site
- Mayo Clinic Florida
- Registry record
- NCT06972056 · updated
A Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual Migraine
- Phase 3
- Ages 18 to 45
- Female participants
- Sponsor
- Pfizer
- Study site
- Jacksonville Center for Clinical Research
- Registry record
- NCT06641466 · updated
Source: ClinicalTrials.gov. Data processed . See every migraine study recruiting in Jacksonville, FL on ClinicalTrials.gov.
Ask about studies near Jacksonville
Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.
Before you contact a study
How taking part works
From your first question to your decision: what happens and who you talk to along the way.
Questions to ask a study team
What to ask about time, risks and your rights before you agree to anything.
Eligibility and screening
How a study team works out whether a study is suitable for you.
About these listings
These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 17, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded. This site lists only studies that test a medication, as each study is coded in the registry.
CNS Medication Trials does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.
Sources and further reading
- ClinicalTrials.gov study registry — ClinicalTrials.gov (National Library of Medicine)
- Terms and Conditions for use of ClinicalTrials.gov data — ClinicalTrials.gov (National Library of Medicine)
- Questions to Ask About Volunteering for a Research Study — HHS Office for Human Research Protections